COVID-19
Shionogi's Ensitrelvir NDA Accepted by US FDA for COVID-19 Post-Exposure Prevention
Shionogi & Co., Ltd. has announced that the US FDA has accepted the New Drug Application (NDA) for ensitrelvir, an oral antiviral therapy for the prevention of COVID-19 following exposure to an infected individual. This marks a significant milestone in the development of ensitrelvir, which has shown promise in preventing